Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 169-175

  Rahman, Masmudur M ^a   Madlambayan, Gerard J ^b   Cogle, Christopher R ^b   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ABMT; Acute myelogenous leukemia; Ex vivo purging; Hematopoietic stem and progenitor cells; Myxoma virus; Oncolytic virus

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALEMTUZUMAB; CIDOFOVIR; CISPLATIN; CYTARABINE; ETOPOSIDE; FLUCYTOSINE; FLUOROURACIL; IDARUBICIN; JX 594; MAFOSFAMIDE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; ONYX 015; PROTEIN KINASE B; PSEUDOMONAS EXOTOXIN; RAPAMYCIN; RHODAMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW PURGING; BRAIN METASTASIS; BREAST CANCER; CANCER STEM CELL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GENETIC ENGINEERING; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LUNG METASTASIS; MEDULLOBLASTOMA; MELANOMA B16; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; RHABDOID TUMOR; SPINAL CORD METASTASIS; TERATOMA; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; AUTOTRANSPLANTATION; GENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MYXOMA VIRUS; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; BONE MARROW PURGING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYXOMA VIRUS; NEOPLASTIC STEM CELLS; ONCOLYTIC VIRUSES; TRANSPLANTATION, AUTOLOGOUS;

MYXOMA VIRUS; POXVIRIDAE;

EID: 77953538303     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.010     Document Type: Review

References (76)

1. Kvalheim G. Purging of autografts: methods and clinical significance. Ann Med 1996, 28:167-173.
2. Gribben J.G., Nadler L.M. Bone marrow purging for autologous bone marrow transplantation. Leuk Lymphoma 1993, 11(Suppl. 2):141-148.
3. Rill D.R., Santana V.M., Roberts W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
4. Motta M.R., Mangianti S., Rizzi S., et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Exp Hematol 1997, 25:1261-1269.
5. Strauss G., Westhoff M.A., Fischer-Posovszky P., et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ 2008, 15:332-343.
6. Abonour R., Scott K.M., Kunkel L.A., et al. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 1998, 22:957-963.
7. Spyridonidis A., Schmidt M., Bernhardt W., et al. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood 1998, 91:1820-1827.
8. Gee A., Moss T., Mansour V., et al. Large-scale immunomagnetic separation system for the removal of tumor cells from bone marrow. Prog Clin Biol Res 1992, 377:181-187.
9. Thirukkumaran C.M., Russell J.A., Stewart D.A., Morris D.G. Viral purging of haematological autografts: should we sneeze on the graft?. Bone Marrow Transplant 2007, 40:1-12.
10. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
11. Kvalheim G., Wang M.Y., Pharo A., et al. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother 1996, 5:427-436.
12. Zhong R.K., Donnenberg A.D., Rubin J., Ball E.D. Differential effect of 4-hydroperoxycyclophosphamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging. Blood 1994, 83:2345-2351.
13. Shimoni A., Korbling M. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?. Crit Rev Oncol Hematol 2002, 41:241-250.
14. Cripe T.P., Wang P.Y., Marcato P., Mahller Y.Y., Lee P.W. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009, 17:1677-1682.
15. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4:101-117.
16. Roberts M.S., Lorence R.M., Groene W.S., Bamat M.K. Naturally oncolytic viruses. Curr Opin Mol Ther 2006, 8:314-321.
17. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885.
18. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006, 98:298-300.
19. Liu T.C., Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007, 67:429-432.
20. Mastrangelo M.J., Maguire H.C., Eisenlohr L.C., et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999, 6:409-422.
21. Freytag S.O., Khil M., Stricker H., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002, 62:4968-4976.
22. Hu J.C., Booth M.J., Tripuraneni G., et al. A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow. Clin Cancer Res 2006, 12:6853-6862.
23. Wu A., Mazumder A., Martuza R.L., et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res 2001, 61:3009-3015.
24. Lichty B.D., Stojdl D.F., Taylor R.A., et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004, 15:821-831.
25. Thirukkumaran C.M., Luider J.M., Stewart D.A., et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003, 102:377-387.
26. Thirukkumaran C.M., Luider J.M., Stewart D.A., et al. Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts. Bone Marrow Transplant 2005, 35:1055-1064.
27. Lillo R., Ramirez M., Alvarez A., et al. Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Res 2002, 62:5013-5018.
28. Wagner L.M., Guichard S.M., Burger R.A., et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002, 62:5001-5007.
29. Wolff G., Korner I.J., Schumacher A., Arnold W., Dorken B., Mapara M.Y. Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation. Hum Gene Ther 1998, 9:2277-2284.
30. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009, 9:64-71.
31. Shen Y., Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005, 11:180-195.
32. Thorne S.H., Bartlett D.L., Kirn D.H. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?. Curr Gene Ther 2005, 5:429-443.
33. Worschech A., Haddad D., Stroncek D.F., Wang E., Marincola F.M., Szalay A.A. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009, 58:1355-1362.
34. Gilbert P.A., McFadden G. Poxvirus cancer therapy. Recent Pat Antiinfect Drug Discov 2006, 1:309-321.
35. Guo Z.S., Thorne S.H., Bartlett D.L. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008, 1785:217-231.
36. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005, 3:201-213.
37. Mercer J., Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 2008, 320:531-535.
38. Moss B. Poxvirus entry and membrane fusion. Virology 2006, 344:48-54.
39. Putz M.M., Midgley C.M., Law M., Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 2006, 12:1310-1315.
40. Vora S., Damon I., Fulginiti V., et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46:1555-1561.
41. Stanford M.M., McFadden G. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 2007, 7:1415-1425.
42. Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol Rev 2000, 24:123-133.
43. Stanford M.M., Werden S.J., McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res 2007, 38:299-318.
44. Barrett J.W., Cao J.X., Hota-Mitchell S., McFadden G. Immunomodulatory proteins of myxoma virus. Semin Immunol 2001, 13:73-84.
45. Kerr P., McFadden G. Immune responses to myxoma virus. Viral Immunol 2002, 15:229-246.
46. Zuniga M.C. A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation. Virus Res 2002, 88:17-33.
47. Wang F., Ma Y., Barrett J.W., et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 2004, 5:1266-1274.
48. Wang F., Gao X., Barrett J.W., et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 2008, 4:e1000099.
49. Bartee E., Mohamed M.R., Lopez M.C., Baker H.V., McFadden G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol 2009, 83:498-511.
50. Sypula J., Wang F., Ma Y., Bell J., McFadden G. Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 2004, 8:103-114.
51. Bartee E., McFadden G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine 2009, 47:199-205.
52. Wang G., Barrett J.W., Stanford M., et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006, 103:4640-4645.
53. Stanford M.M., Shaban M., Barrett J.W., et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2008, 16:52-59.
54. Tokunaga E., Oki E., Egashira A., et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008, 8:27-36.
55. Werden S.J., McFadden G. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta 2008, 1784:228-237.
56. Stanford M.M., Barrett J.W., Nazarian S.H., Werden S., McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2007, 81:1251-1260.
57. Lun X.Q., Zhou H., Alain T., et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007, 67:8818-8827.
58. Katsafanas G.C., Moss B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J Biol Chem 2004, 279:52210-52217.
59. Yang H., Kim S.K., Kim M., et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005, 115:379-387.
60. Soares J.A., Leite F.G., Andrade L.G., et al. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J Virol 2009, 83:6883-6899.
61. Lun X., Yang W., Alain T., et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005, 65:9982-9990.
62. Wu Y., Lun X., Zhou H., et al. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 2008, 14:1218-1227.
63. Fenner F., Ratcliffe F. Myxomatosis 1965, University Press, Cambridge.
64. Barrett J.W., Alston L.R., Wang F., et al. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol 2007, 13:549-560.
65. Kim M., Madlambayan G.J., Rahman M.M., et al. Myxoma virus targets primary human leukemia stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009, 23:2313-2317.
66. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
67. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
68. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
69. Martelli A.M., Nyakern M., Tabellini G., et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928.
70. Shpall E.J., Jones R.B., Bast R.C., et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991, 9:85-93.
71. Cheson B.D. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006, 33:S2-S14.
72. Mohr M., Dalmis F., Hilgenfeld E., et al. Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2001, 7:51-57.
73. Goggins T.F., Chao N. Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. Leuk Lymphoma 2003, 44:1871-1879.
74. Keir M., Fiddes R., Biggs J.C., Kearney P.P. Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections. Stem Cells 2000, 18:422-427.
75. Carella A.M., Lerma E., Corsetti M.T., et al. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999, 93:1534-1539.
76. Bhatia S., Sather H.N., Heerema N.A., Trigg M.E., Gaynon P.S., Robison L.L. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002, 100:1957-1964.